Related Experiment Video
Updated: May 27, 2025
Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
Therapeutic delivery - industry update covering October 2024
1Global Pharma Segment, Phillips Medisize, Cambridge, UK.
None:
This Industry Update covers the period from 1st October through to 31 October 2024 and is based on information sourced from company press releases, scientific literature, patents, and various news websites. This month saw two biotech company acquisitions being made by larger biopharma companies with Modifi Biosciences, a company focussing on the development of novel small molecule anticancer therapeutics, being acquired Merck, and AbbVie acquiring Aliada Therapeutics, which focuses on the treatment of central nervous system disorders. Elektrofi and Archon Biosciences both announced new investments, respectively, to support the development of novel high concentration subcutaneous drug delivery technology and for the development Antibody cages for therapeutic applications. GSK and Cambridge University announced a new five-year collaboration focusing on kidney and respiratory disease, and Aeropump and Resyca announced the launch of a new soft mist nasal delivery system that they have been jointly developing. UCB gained FDA approval for a higher dose of its injectable drug, BIMZELX for the treatment of autoimmune disorders, and AbbVie FDA approval for a continuous infusion treatment for Parkinson's Disease. Eisai announced it has completed its submission to the FDA for a subcutaneous version of its already approved therapy for Alzheimer's Disease. Clinical research updates included Johnson and Johnson announcing termination of a Phase III trial evaluating an implanted combination device for the treatment of bladder cancer, and Lilly announced positive results for modified dosing regimen for its approved Alzheimer's drug, Kisunla (donanemab).In October, the PDA held its annual Universe of Prefilled Syringes conference at which several updates on developments in injectable drug delivery were made. Scientific updates relating to therapeutic delivery included: a controlled drug delivery technology that enables a complete course of antibiotics to be delivered; a new lipid-based delivery system that improves the safety and efficacy of gene therapies; and the use of tiny controllable robots to enable targeted drug delivery of multiple therapeutics.
Related Concept Videos
01:16Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:29Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
01:11Clinical Trials: Overview
01:29Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...